Seasonal Influenza Vaccine Effectiveness, 2012-2013
Age | Number | % Total |
---|---|---|
6 months-8 years | 1,509 | 23 |
9-17 years | 981 | 15 |
18-49 years | 2,267 | 35 |
50-64 years | 1,040 | 16 |
65+ years | 655 | 10 |
Gender | Number | % Total |
---|---|---|
Male | 2,654 | 41 |
Female | 3,798 | 59 |
On This Page
- Patients by Age
- Patients by Gender
- Patients by Race
- Influenza Virus Type And Subtype Among Influenza-Positive Patients
- Vaccine Effectiveness for all Vaccine Types Against influenza A or B viruses
- Vaccine Effectiveness for all Vaccine Types Against Influenza A (H3N2) viruses
- Vaccine Effectiveness for all Vaccine Types Against Influenza B/Yamagata lineage viruses
- Vaccine Effectiveness for all Vaccine Types Against Influenza B/Victoria lineage viruse
Race | Number | % Total |
---|---|---|
White, non-Hispanic | 4,866 | 76 |
Black, non-Hispanic | 512 | 8 |
Hispanic | 541 | 8 |
Other, non-Hispanic | 520 | 8 |
Coinfections present include: 5 cases coinfected with Influenza A (H3N2) and Influenza B Yamagata; 1 case coinfected with Influenza A (H3N2) and Influenza B Yamagata (lineage not determined); 1 case coinfected with Influenza A (not subtyped) and Influenza B Yamagata; 3 cases coinfected with Influenza B Yamagata and Influenza B/Victoria
Top of Page Top of Page- Page last reviewed: September 4, 2018
- Page last updated: September 4, 2018
- Content source:
- Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD)
- Page maintained by: Office of the Associate Director for Communication, Digital Media Branch, Division of Public Affairs